Novo Nordisk Shares Outstanding 2006-2019 | NVO

Novo Nordisk shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Novo Nordisk shares outstanding for the quarter ending September 30, 2019 were 2.373B, a 1.9% decline year-over-year.
  • Novo Nordisk 2018 shares outstanding were 2.424B, a 2.17% decline from 2017.
  • Novo Nordisk 2017 shares outstanding were 2.478B, a 2.23% decline from 2016.
  • Novo Nordisk 2016 shares outstanding were 2.535B, a 1.67% decline from 2015.
Novo Nordisk Annual Shares Outstanding
(Millions of Shares)
2018 2,424
2017 2,478
2016 2,535
2015 2,578
2014 2,630
2013 2,694
2012 2,758
2011 2,851
2010 2,927
2009 2,996
2008 3,103
2007 3,159
2006 3,229
2005 3,293
Novo Nordisk Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 2,373
Q2 2019 2,384
Q1 2019 2,395
Q4 2018 2,424
Q3 2018 2,419
Q2 2018 2,431
Q1 2018 2,442
Q4 2017 2,478
Q3 2017 2,469
Q2 2017 2,484
Q1 2017 2,500
Q4 2016 2,535
Q3 2016 2,531
Q2 2016 2,541
Q1 2016 2,550
Q4 2015 2,578
Q3 2015 2,572
Q2 2015 2,584
Q1 2015 2,604
Q4 2014 2,630
Q3 2014 2,622
Q2 2014 2,637
Q1 2014 2,653
Q4 2013 2,694
Q3 2013 2,682
Q2 2013 2,703
Q1 2013 2,724
Q4 2012 2,758
Q3 2012 2,739
Q2 2012 2,762
Q1 2012 2,803
Q4 2011 2,810
Q3 2011 2,841
Q2 2011 2,869
Q1 2011 2,884
Q4 2010 2,888
Q3 2010 2,912
Q2 2010 2,945
Q1 2010 2,965
Q4 2009 2,976
Q3 2009 3,007
Q2 2009 3,015
Q1 2009 3,064
Q4 2008 3,072
Q3 2008 3,093
Q2 2008 3,118
Q1 2008 3,132
Q4 2007 3,148
Q3 2007 3,182
Q2 2007
Q1 2007 3,191
Q4 2006 3,194
Q3 2006 3,247
Q2 2006 3,233
Q1 2006 3,250
Q4 2005 3,232
Q3 2005 3,275
Q2 2005 3,315
Q1 2005 3,320
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $142.862B $17.724B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $393.465B 17.22
Roche Holding AG (RHHBY) Switzerland $282.089B 0.00
Merck (MRK) United States $219.591B 17.01
Novartis AG (NVS) Switzerland $218.959B 18.48
Pfizer (PFE) United States $211.071B 12.93
Eli Lilly (LLY) United States $133.708B 24.69
AstraZeneca (AZN) United Kingdom $130.139B 23.51
AbbVie (ABBV) United States $123.881B 9.71
Sanofi (SNY) France $120.875B 14.85
GlaxoSmithKline (GSK) United Kingdom $116.729B 14.14
Bristol-Myers Squibb (BMY) United States $105.594B 14.76
Bayer (BAYRY) Germany $77.999B 11.55
H Lundbeck (HLUYY) Denmark $8.192B 14.23